ArticleFrontiers in pharmacology2023

The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB.

Shike Lou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.